Cantor Fitzgerald Initiates Coverage on IMV (TSE:IMV)

Cantor Fitzgerald began coverage on shares of IMV (TSE:IMV) in a research note issued to investors on Wednesday, Price Targets.com reports. The brokerage set a “buy” rating and a C$4.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 85.19% from the stock’s previous close.

IMV has been the topic of a number of other reports. National Bank Financial reissued a “sector perform market weight” rating on shares of IMV in a research note on Wednesday, August 11th. Raymond James decreased their price target on IMV to C$2.50 and set a “market perform” rating on the stock in a research note on Friday, July 16th. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, IMV has a consensus rating of “Hold” and a consensus price target of C$3.75.

IMV stock opened at C$2.16 on Wednesday. The stock has a market cap of C$177.43 million and a PE ratio of -3.90. The stock has a 50-day moving average price of C$2.11 and a 200 day moving average price of C$2.87. IMV has a 52 week low of C$1.68 and a 52 week high of C$6.29. The company has a current ratio of 5.11, a quick ratio of 4.25 and a debt-to-equity ratio of 39.14.

IMV (TSE:IMV) last issued its quarterly earnings results on Wednesday, August 11th. The company reported C($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C($0.14). The business had revenue of C$0.05 million during the quarter. On average, equities analysts predict that IMV will post -0.5 EPS for the current year.

About IMV

IMV Inc, a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma.

Featured Story: Why are percentage gainers important?

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.